Navigation Links
FDA Approves PRE-PEN Penicillin Allergy Test
Date:9/30/2009

ALK-Abelló, Inc., and AllerQuest, LLC, are pleased to announce the return of PRE-PEN® penicillin allergy skin testing products to the market. PRE-PEN® received full FDA approval on September 18, 2009. ALK-Abelló has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN®.

Round Rock, TX (PRWEB) September 30, 2009 -- ALK-Abelló, Inc., and AllerQuest, LLC, are pleased to announce the return of PRE-PEN® to the market. Under the terms of the agreement, ALK will be the exclusive distributor of PRE-PEN®. PRE-PEN® received full FDA approval on September 18, 2009.

ALK-Abelló has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN® penicillin skin testing products. AllerQuest will manufacture the product in their FDA approved production facility in Plainville, Connecticut.

PRE-PEN® was a widely used skin test product for more than 30 years. In 2004, PRE-PEN® was withdrawn from the marketplace due to the lack of a dedicated penicillin manufacturing facility from the previous supplier. The loss of this product severely limited a physician's ability to test for penicillin sensitivity. In 2005, AllerQuest was formed to resurrect production of PRE-PEN® so that allergy specialists and hospitals could again have a skin test for penicillin sensitivity.

Jose A. Moreno Toscano, President of ALK-Abelló, Inc., stated, "ALK is excited to be the exclusive provider of PRE-PEN®. Our focus continues to be in providing allergy specialists with unique products such as PRE-PEN®, and value added services to assist with fighting the cause of allergy and driving more patients to the specialist for proper diagnosis and treatment of allergic disease."

Dr. Louis Mendelson, President of AllerQuest, LLC stated, "More than 30 million Americans are suspected to be allergic to penicillin, but extensive studies have demonstrated that most of these people may be able to be treated safely with penicillin and related antibiotics. In past years, in the absence of a penicillin test, allergy specialists were unable to test patients for penicillin sensitivity. AllerQuest has invested significant time and resources to bring this important product back into the US market, and we are pleased to bring this product to market with a company like ALK, which possesses strengths in marketing and world-wide distribution critical to the successful re-launching of PRE-PEN®."

Additional information can be found at www.pre-pen.com.

About ALK
ALK is a research driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy) - a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Further information is available at www.alk-abello.us

About AllerQuest, LLC
AllerQuest's mission is to develop skin test reagents to safely and accurately identify patients who are at risk for potentially life-threatening reactions to penicillin antibiotics. The company strives to ensure a reliable source of high quality test reagents to assist physicians in the diagnosis of penicillin allergy. Further information is available at www.allerquest.com

###

Read the full story at http://www.prweb.com/releases/ALKAbello/PrePen/prweb2973314.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. FDA Approves Donor Screening Test for Antibodies to HIV
2. ClearWay Minnesota(SM) Board Approves New Officers
3. FDA Approves Vaccines for 2009 H1N1 Influenza Virus
4. FDA Approves 4 Swine Flu Vaccines
5. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
6. FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
7. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
8. First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Programs Viability
9. Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
10. FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
11. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, ... Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist by ... directory that recognizes local physicians and dentists who have earned high ratings and superior ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior Lake, ... the Minneapolis Home and Garden Show which is being held February 24 through 26 ... is the Minneapolis Convention Center. , From its broad line of sit stand ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- Nevro Corp. (NYSE: NVRO), a global medical device company ... chronic pain, today reported financial results for the three months ... 2016 Accomplishment & Highlights: Achieved revenue of ... 228% as reported, over the prior year U.S. ... over the prior year International revenue of ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: